Engineering and In Vitro Selection of a Novel AAV3B Variant with High Hepatocyte Tropism and Reduced Seroreactivity

Engineering and In Vitro Selection of a Novel AAV3B Variant with High Hepatocyte Tropism and Reduced Seroreactivity

Limitations to successful gene therapy with adeno-associated virus (AAV) can comprise pre-existing neutralizing antibodies to the vector capsid that can block cellular entry, or inefficient transduction of target cells that can lead to sub-optimal expression of the therapeutic transgene. Recombinant...

Full description

Bibliographic Details
Main Authors: Moanaro Biswas, Damien Marsic, Ning Li, Chenhui Zou, Gloria Gonzalez-Aseguinolaza, Irene Zolotukhin, Sandeep R.P. Kumar, Jyoti Rana, John S.S. Butterfield, Oleksandr Kondratov, Ype P. de Jong, Roland W. Herzog, Sergei Zolotukhin
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
AAV3
gene therapy
hepatocyte
directed evolution
seroprevalence
neutralizing antibody
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050120302047

Internet

http://www.sciencedirect.com/science/article/pii/S2329050120302047

Similar Items